Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
43.4M
-
Number of holders
-
42
-
Total 13F shares, excl. options
-
6.07M
-
Shares change
-
+1.59M
-
Total reported value, excl. options
-
$51.2M
-
Value change
-
+$13.4M
-
Number of buys
-
29
-
Number of sells
-
-7
-
Price
-
$8.43
Significant Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) as of Q3 2019
44 filings reported holding CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share as of Q3 2019.
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) has 42 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.07M shares
of 43.4M outstanding shares and own 13.99% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (1.38M shares), BlackRock Inc. (1.22M shares), Slate Path Capital LP (890K shares), VANGUARD GROUP INC (755K shares), 683 Capital Management, LLC (300K shares), STATE STREET CORP (286K shares), NORTHERN TRUST CORP (224K shares), GEODE CAPITAL MANAGEMENT, LLC (211K shares), Nuveen Asset Management, LLC (70K shares), and HSBC HOLDINGS PLC (68.1K shares).
This table shows the top 42 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.